Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dutasquare** is a marketed oral pharmaceutical product from **Golden Square** for **benign prostatic hyperplasia**. Based on the naming convention, therapeutic category placement under Anti BPH, and common Indian branded-generic practice, it most likely represents a **dutasteride** product, a small-molecule **5-alpha-reductase inhibitor** that reduces conversion of testosterone to dihydrotestosterone and thereby lowers prostatic androgen signaling and prostate volume over time. However, the company material provided lists the brand name only and does not disclose the exact active ingredient, strength, dosage form, or formal prescribing details, so some annotations below are inferred with moderate uncertainty from the brand identity and indication context rather than explicit label information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dutasquare.